They are most commonly used alongside primary weight loss medications like semaglutide or tirzepatide, but are also available as a standalone option
Leaky Gut and Neuroinflammation BPC-157 acts as a membrane stabilizer, counteracting increased intestinal permeability (leaky gut syndrome) associated with depression pathophysiology, cognitive dysfunction in schizophrenia, and breakdown of paracellular pathways in deficit schizophrenia
In contrast, injections can show results in just a few days
The blend offers convenience for researchers running protocols that would otherwise require two separate vials
Depending on the clinical response, continue treatment with the reduced dose
The Ghost Trial In the late 1990s and early 2000s, the Croatian pharmaceutical company Pliva sponsored clinical trials for BPC-157 as a treatment for inflammatory bowel disease